AstraZeneca/BARDA In Antibiotics Deal; $170m Potential
This article was originally published in Scrip
Executive Summary
AstraZeneca has entered into a public-private partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop new antibacterials intended to address biothreat pathogens, in addition to antibiotic resistance, under a "portfolio" approach, which will allow the U.S. government funds to be steered away from a product that proves to be unsuccessful early on in the R&D process to other promising candidates.